Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 127093901 | 12709390 | 1 | I | 1999 | 20060130 | 20160901 | 20160901 | PER | US-ASTRAZENECA-2006BM02052 | ASTRAZENECA | 42.00 | YR | F | Y | 89.80000 | KG | 20160902 | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 127093901 | 12709390 | 1 | PS | BYETTA | EXENATIDE | 1 | Subcutaneous | 5 ???G, BID | 21773 | 5 | UG | SOLUTION FOR INJECTION IN PRE-FILLED PEN | BID | ||||||
| 127093901 | 12709390 | 2 | SS | CRESTOR | ROSUVASTATIN CALCIUM | 1 | Oral | U | U | 0 | 20 | MG | TABLET | QD | |||||
| 127093901 | 12709390 | 3 | SS | CRESTOR | ROSUVASTATIN CALCIUM | 1 | Oral | U | U | 0 | 20 | MG | TABLET | QD | |||||
| 127093901 | 12709390 | 4 | SS | PRILOSEC | OMEPRAZOLE MAGNESIUM | 1 | Oral | 102280 | MG | 0 | 40 | MG | QD | ||||||
| 127093901 | 12709390 | 5 | SS | XIGDUO XR | DAPAGLIFLOZIN PROPANEDIOLMETFORMIN HYDROCHLORIDE | 1 | Oral | ONE TABLET 2 TIMES DAILY | 0 | TABLET | |||||||||
| 127093901 | 12709390 | 6 | SS | XIGDUO XR | DAPAGLIFLOZIN PROPANEDIOLMETFORMIN HYDROCHLORIDE | 1 | Oral | 1000/5 TWO TABLETS AT NIGHT | 0 | TABLET | |||||||||
| 127093901 | 12709390 | 7 | C | ZETIA | EZETIMIBE | 1 | 0 | 10 | MG | QD | |||||||||
| 127093901 | 12709390 | 8 | C | REGULAR ASPIRIN | ASPIRIN | 1 | 0 | QD | |||||||||||
| 127093901 | 12709390 | 9 | C | TUJEO | 2 | 0 | 32 | IU | QD | ||||||||||
| 127093901 | 12709390 | 10 | C | VICTOZA | LIRAGLUTIDE | 1 | 0 | 5 | MG | QD | |||||||||
| 127093901 | 12709390 | 11 | C | BYSTOLIC | NEBIVOLOL HYDROCHLORIDE | 1 | 0 | ||||||||||||
| 127093901 | 12709390 | 12 | C | LOSARTAN. | LOSARTAN | 1 | 0 | 40 | MG | QD | |||||||||
| 127093901 | 12709390 | 13 | C | VITAMIN D | CHOLECALCIFEROL | 1 | 0 | ||||||||||||
| 127093901 | 12709390 | 14 | C | GLYBURIDE. | GLYBURIDE | 1 | 5 MG, QD | 0 | 5 | MG | QD |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 127093901 | 12709390 | 1 | Type 2 diabetes mellitus |
| 127093901 | 12709390 | 2 | Blood cholesterol abnormal |
| 127093901 | 12709390 | 3 | Blood cholesterol abnormal |
| 127093901 | 12709390 | 4 | Gastrooesophageal reflux disease |
| 127093901 | 12709390 | 5 | Diabetes mellitus |
| 127093901 | 12709390 | 6 | Diabetes mellitus |
| 127093901 | 12709390 | 9 | Diabetes mellitus |
| 127093901 | 12709390 | 10 | Blood pressure abnormal |
| 127093901 | 12709390 | 11 | Blood pressure measurement |
| 127093901 | 12709390 | 12 | Blood pressure abnormal |
| 127093901 | 12709390 | 14 | Type 2 diabetes mellitus |
Outcome of event
| no results found |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 127093901 | 12709390 | Anaemia | |
| 127093901 | 12709390 | Back disorder | |
| 127093901 | 12709390 | Blood cholesterol increased | |
| 127093901 | 12709390 | Diabetes mellitus | |
| 127093901 | 12709390 | Drug dose omission | |
| 127093901 | 12709390 | Muscle spasms | |
| 127093901 | 12709390 | Nausea | |
| 127093901 | 12709390 | Off label use | |
| 127093901 | 12709390 | Renal tumour excision |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 127093901 | 12709390 | 1 | 20060119 | 0 | ||
| 127093901 | 12709390 | 2 | 2016 | 0 | ||
| 127093901 | 12709390 | 4 | 2008 | 0 |